Patient info Search Menu

Boots Antiseptic Cream – Summary of Product Characteristics (SmPC) for healthcare professionals

Updated:
Key facts
Status:
No longer supplied
Medicine strength:
5 mg/gram + 5 mg/gram + 2 mg/gram
Contains active substances:

Summary of Product Characteristics (SmPC) - Boots Antiseptic cream

1 NAME OF THE MEDICINAL PRODUCT

Boots Antiseptic Cream

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients % w/w 2, 4 Dichlorobenzyl alcohol HSE 0.5% Cetrimide EP 0.5% Allantoin BPC' 34 BPC 0.2%

Excipient(s) with known effect

Cetostearyl alcohol 10% w/w

Fragrance containing allergen (in Perfume Compound AG 8053 CPL)

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Cream

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For abrasions, minor burns and scalds, small areas of sunburn, dry chapped skin, nappy rash, insect bites, spots and pimples.

4.2 Posology and method of administration

Adults, Children and Elderly:

Apply the cream gently to the affected area two or three times a day.

For topical application.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Prolonged and repeated applications are inadvisable as hypersensitivity may occur.

If symptoms persist, consult your doctor.

For external use only.

Keep all medicines out of the reach of children.

Information about some of the ingredients

This medicine contains cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).

This medicine contains fragrance with lilial which may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant interactions known.

4.6 Fertility, pregnancy and lactation

The safety of antiseptic cream during pregnancy and lactation has not been established, but use during these periods is not considered to constitute a hazard.

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

Hypersensitivity reactions may occasionally occur in certain individuals following repeated application.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Where excessive application has been made to the skin, excess cream should be removed and the area washed with soap and water. Otherwise no further treatment is necessary.

In case of ingestion, the product may cause burns and irritation in the mouth and oesophagus. If any treatment is required at all, milk should be given to drink, otherwise symptomatic/supportive therapy should be given.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Dichlorobenzyl alcohol has antiseptic properties. Cetrimide is a quarternary ammonium antiseptic which has bactericidal activity against both gram-positive and gram negative organisms. Allantoin is claimed to stimulate tissue formation and hasten wound healing.

5.2 Pharmacokinetic properties

Not available.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Hyetellose (Hydroxyethyl Cellulose) Cetostearyl Alcohol

Ceresin

Light Liquid Paraffin

Cetomacrogol 1000

Dimethicone 20

Polyethylene Glycol 300

Perfume Compound AG 8053 CPL (containing lilial) Sodium Citrate Granular

Anhydrous Citric Acid Granular Purified Water

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Do not store above 30°C.

6.5 Nature and contents of container

Internally lacquered collapsible aluminium tube having a membrane seal and cap, in a cardboard carton.

Pack sizes: 15, 20, 25, 30, 35, 40, 50, 60, 75, 80, 100, 120g.

Laminate tube with polypropylene cap in a cardboard carton. Pack sizes: 15, 20, 25, 30, 35, 40, 50, 60, 75, 80, 100, 120g.

Laminate tube with polypropylene cap and polythene/aluminium membrane seal in a cardboard carton.

Pack sizes: 15, 20, 25, 30, 35, 40, 50, 60, 75, 80, 100, 120g.

6.6 Special precautions for disposal

Not applicable

7 MARKETING AUTHORISATION HOLDER

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA

8 MARKETING AUTHORISATION NUMBER(S)

PL 00014/5138R

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

Date of First Authorisation: 7 November 1984 Last Renewal: 15 June 1995

10 DATE OF REVISION OF THE TEXT

08/07/2024

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00014/5138

Last revision stated in the text: 8 July 2024 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Boots Antiseptic cream

What these facts mean

Active substances? Cetrimide, Allantoin, Dichlorobenzyl alcohol
Strength? 5 mg/gram + 5 mg/gram + 2 mg/gram
Pharmaceutical form? Cutaneous cream
How is it taken? Cutaneous
Excipients? Hyetellose (Hydroxyethyl Cellulose) Cetostearyl Alcohol, Ceresin, Light Liquid Paraffin, Cetomacrogol 1000, Dimethicone 20, Polyethylene Glycol 300, Perfume Compound AG 8053 CPL (containing lilial) Sodium Citrate Granular, Anhydrous Citric Acid Granular Purified Water
Is it available?? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 24 months
Storage Do not store above 30°C.
Marketing authorisation? PL 00014/5138 (first authorised 7 November 1984)
Marketing authorisation holder? The Boots Company PLC
Codes? BNF 13100500

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.0.0 of 2 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.